and to investigate if aCL increase relates to the underlying etiology.
MATERIALS AND METHODS
This study is to investigate the frequency of increased aCL in cerebral ischemia in the Taiwanese population, and the relation between increased aCL and different etiologies of cerebral ischemia.
Population Sampling
Patients older than 20 years presenting with cerebral ischemia were enrolled. Patients with parenchymal hemorrhage, epidural hemorrhage, subdural hemorrhage, ventricular hemorrhage, venous thrombosis, or transient ischemic attack were excluded. The diagnosis of cerebral ischemia was an acute onset of focal neurologic deficit explained by vascular cause. The etiology of cerebral ischemia was classified into five subtypes: large-artery atherosclerosis, small-artery occlusive disease (lacunes), cardioembolism, stroke of other known etiology, and stroke of unknown etiology (Table 1 ). This classification is adopted in part to the TOAST study in that five subtypes are categorized: large-artery atherosclerosis, small-artery occlusive disease, cardioembolism, stroke of other determined etiology, and stroke of undetermined etiology (Table  1 ) (9) . In the TOAST study, the subtype definitions are based on risk factor profiles, clinical features, and results of diagnostic tests. The diagnosis of stroke of undetermined etiology in TOAST can be made when two or more likely causes are detected or when no cause has been found. Patient with an increase of aCL will be categorized into stroke of other determined etiology, or stroke of undetermined etiology when another risk factor is present. Therefore, three problems are encountered in TOAST classification. First, many tests, such as aCL, lupus anticoagulant, protein C, protein S, or antithrombin III, are not routine work in TOAST study. Second, a presence of increased aCL will change the classification to either stroke of other determined etiology or stroke of undetermined etiology. Third, stroke of undetermined etiology contains a variety of medical conditions with different contributions to cerebral ischemia. To solve problems, we make two changes. First, we do not include aCL into categorization. Second, stroke of unknown etiology includes patient without any known risk factor, in contrast to stroke of unknown etiology includes patient with either no or multiple risk factor in TOAST study ( Table 1) . The diagnostic criteria of large-artery atherosclerosis, small-artery occlusive disease and cardioembolism are identical to those of the TOAST study. Stroke of other known etiology includes patients with causes such as coagulopathy, hematologic disorders, and nonatherosclerotic vasculopathy. Patients with multiple etiologies are excluded. Therefore, the underlying etiology of cerebral ischemia is simplified and unified in this series.
In this study, exclusion of patients was further established by the presence of any of the following: (1) a history of systemic lupus erythemato- (10, 11) . One hundred healthy subjects free of medical and neurologic disorders were included as control subjects. They were either hospital employees, family of patients observed in the neurology clinic, or individuals asking for neurologic examination.
The definition of hypertension was systole greater than 140 mmHg and/or diastole greater than 90 mmHg in three occasional measurements or under hypotensive treatment. Diabetes mellitus was an increase of fasting blood sugar greater than 150 mg/dL on two occasions and glycohemoglobin greater than 6.2% or under antidiabetic treatment. Hypercholesterolemia was serum total cholesterol level greater than 200 mg/dL or low-density lipoprotein cholesterol greater than 120 mg/dL. Hypertriglyceridemia was defined as a serum triglyceride level greater than 180 mg/dL.
Baseline Examination
The stroke risk factor survey (12) (13) (14) was performed in each patient and control, including biochemistry (total proteins, globulins, albumin, aspartate aminotransferase, alanine aminotransferase, creatinine, blood urea nitrogen, uric acid, cholesterol, triglyceride, cholesterol electrophoresis, electrolytes), hematology (complete blood cell count, erythrocyte sedimentation rate), rheology (serum viscosity, prothrombin time, activated partial thromboplastin time, fibrinogen protein C, antithrombin III), C-reactive protein, venereal disease research laboratory, and immunology (aCL, lupus anticoagulant, antinuclear antibody). Direct and indirect Coombs' tests were done in case of increased aCL. In each patient, cranial computed tomography, magnetic resonance imaging and angiography, carotid duplex ultrasound, electrocardiography, and transthoracic echography were done. Transesophageal echography and cerebral angiography were optional.
Laboratory Procedures
Venous blood was collected from the antecubital vein using a sterile vacutainer system after an overnight fast of 10 hours. Blood was mixed with 3.8% trisodium citrate (1:9 citrate:blood). For activated partial thromboplastin time, prothrombin time, aCL, and lupus anticoagulant, blood was centrifuged within 1 hour after collection (10 minutes at 3000 g under 4°C) to yield platelet-poor plasma. The activated partial thromboplastin time and prothrombin time were done within 2 hours after collection. The plateletpoor plasma was aliquoted and stored at -20°C for batch measurement within 14 days. For complete blood cell count, blood was examined within 4 hours by Sysmex SE-9000 automated counter (Australian Diagnostics, Sydney, Australia). For total proteins, globulins, albumin, aspartate aminotransferase, alanine aminotransferase, creatinine, blood urea nitrogen, uric acid, cholesterol, triglyceride and electrolytes, serum was examined within 2 hours after collection (Hitachi 7450 autoanalyzer, Tokyo, Japan). Venereal disease research laboratory was tested with a commercial kit (Murex Diagnostics Ltd., Datford, United Kingdom). C-reactive protein was measured using a highly sensitive, latex particle-enhanced immunoassay (Roche Diagnostics GmbH) and the reference range was less than 5.0 µg/dL in our laboratory.
Coagulation Time and Antiphospholipid Antibody Assay
The activated partial thromboplastin time and prothrombin time assays were performed on the Sysmex CA-6000 coagulometer (Australian Diagnostics, Sydney, Australia). Thromboplastins used were APTT-LS (Fisher Diagnostics, VA, USA) for the activated partial thromboplastin time and Innovin (Dade Behring Marburg GmbH, Marburg, Germany) for the prothrombin time. Enzyme-linked immunosorbent assay method was used to measure the IgG isotype of aCL (Varelisa test-kit, Pharmacia & Upjohn, Germany) with human β 2 GPI as cofactor. The lupus anticoagulant was determined by the aPTT (Stago) and confirmed by dilute Russell's viper venom test (LA Screen/LA Confirm, Gradipore Ltd., Australia). For the aCL, the IgG isotype was measured and expressed as GPL/mL. The coefficient variance of intravariation was 4.2% and intervariation was 6.5%, respectively. The cut-off point was 10.0 GPL/mL for aCL. An abnormal increase of aCL-IgG was defined when the level increased over cut-point twice, 6 weeks apart.
Statistical Analysis
Descriptive statistics for continuous variables were reported as mean and standard deviation.
For categorical variables, number and percentage of patients were given. Differences between means were assessed with two-tail student unpaired t-test for independent samples for variables with a normal distribution. R X C contingency test, Chi-Square test, or Fisher's exact test was used for categorical variables. A p value less than 0.05 was accepted as significant.
RESULTS
An abnormal increase of aCL-IgG was achieved in 45 patients at the first examination and in 41 patients at the second examination. Therefore, a definite increase of aCL-IgG was noted in 9.35% patients. On the other hand, aCL-IgG increased in four controls (4.0%). The relative risk of aCL-IgG in cerebral ischemia was 2.52.
The frequency of increased aCL-IgG was 12.2%, 8.8%, 3.5%, 3.9%, and 12.8% in patients of large-artery atherosclerosis, small-artery occlusive disease, cardioembolism, stroke of other known etiology, and stroke of unknown etiology, respectively ( Table 2 ). The diseases in stroke of other known etiology were listed in Table 3 . Neither age nor gender predicted an increase of aCL-IgG. The frequency of increased aCL-IgG did not differ between patients with and without hypertension, diabetes mellitus, hypercholesterolemia, hypertriglyceridemia, or increased Creactive protein ( Table 4 ). The fibrinogen, leukocyte count, and globulin were 319.2 ± 101.3 mg/dL, 7175.4 ± 2013.3/cm 3 , and 2.23 ± 0.79 mg/dL in patients with increased aCL, while 291.6 ± 88.3 mg/dL, 6956.5 ± 1723.4/cm 3 , and 2.18 ± 0.55 mg/dL in patients with normal aCL, respectively. There was no difference between these three variables.
The frequency of abnormal results of activated partial thromboplastin time, antinuclear factor, Coombs' test, and venereal disease research laboratory in these 41 patients was 12.2%, 9.8%, 2.4%, and 12.2%, respectively. In the four patients with a positive antinuclear factor, the type was speckled in two, nucleolar in one, and diffuse in one patient, individually. The titer was less than 80-fold in all patients.
The frequency of increased aCL differed among these five underlying etiologies (5×2 Contingency test, χ 2 =7.13, p<0.05). A significantly higher frequency of increased aCL was found in patients with large-artery atherosclerotic disease (chi-square test, χ 2 =5.12, p<0.025) and stroke of unknown etiology (chi-square test, χ 2 =3.86, p<0.05) had a higher frequency of increased aCL than control.
DISCUSSION
To our knowledge, this study represents the largest reported series of adults with cerebral ischemia in Asia investigating the frequency of abnormally increased aCL, and the relation between increased aCL and underlying etiology.
The prevalence of increased aCL among unselected stroke patients in previous studies has ranged from 1% (15) to 34% (5) and from 0% (16) to 12% (17) in controls. Some case-control studies have shown an association between different types of aCL and cerebral ischemia, but some studies have not (17) (18) (19) . In general, aCL is accepted as a promising risk factor for cerebral ischemia (5, 6, 18) . Regarding aCL-IgG, the prevalence varies greatly from 1% to 25.3% (Table 5 ). Similarly, a discrepancy is also found in Asians. The prevalence of aCL in patients with cerebral ischemia is 9.5% in Japanese (20), 16.4% in Arabian (21) , and 23% in Indian (22) . In Taiwan, Wang and associates (23) reported a 2.4% prevalence in 170 patients with cerebral ischemia. However, the prevalence of aCL is not examined in control subjects in most studies, pledging an unsettled conclusion for the significance of prevalence in those populations. Nevertheless, an increase of relative risk found in our series supports that aCL-IgG is a risk factor for cerebral ischemia in the Taiwanese population. The aCL is classified into β 2 GPI-dependent and β 2 GPI-independent; the former is considered to be pathologic for thrombosis while the latter's function is still debated. Among those studies concerning the prevalence of aCL cerebral ischemia, β 2 GPI-dependent aCL is only examined in the Honolulu Heart Program (24) and our series in this study. The functional type of measured aCL is β 2 GPI-independent in other studies.
In the Honolulu Heart Program, the age-adjusted percentage of male Japanese descendants with a positive β 2 GPI-dependent aCL-IgG is 16.6% in cases of stroke and 12.1% in controls in the Honolulu Heart Program. The reference range of β 2 GPI-dependent aCL-IgG is more than 23 GPL/mL in the Honolulu Heart Program but over 10 GPL/mL in our series. Although method of measurement and gender of subjects may contribute to the great difference of prevalence between these two studies, environmental factors, such as diet, lifestyle, or atmosphere, may also modify the generation of aCL in cerebral ischemia. Considering the interaction between genetic and environmental factors essential for immune response and expression, a highly variable prevalence of aCL may exist in different ethnicities and regions. An increase of aCL-IgG is identified in our patients with large-artery atherosclerosis and stroke of unknown etiology, which implicates a risk factor-dependent generation of aCL in patients with cerebral ischemia. The causal effect of aCL may be debated in large-artery atherosclerosis because generation of antiphospholipid antibody may be an acute response reactive to inflammation, a biologic basis of atherogenesis (25) . This scepsis is strengthened by a number of patients suffering from infection (26) or cardiac myxoma (27) in whom their blood aCL level become normal after a recovery of their underlying diseases. In addition, patients with large-artery atherosclerosis usually carry a high frequency of atherogenic risk factors, such as hypertension and diabetes mellitus, that are known to aggravate inflammatory reaction and provoke humoral immunity.
These debates may be solved in our results. First, C-reactive protein, fibrinogen, and leukocyte count do not change in parallel with aCL, suggesting the increase of aCL is not likely a result of an inflammatory reaction in large-artery atherosclerosis. Second, the frequency of increased aCL does not differ between patients with or without hypertension or diabetes mellitus in this series. Third, the serum globulin level does not differ in patients with or without an increased aCL. In fact, previous reports do not reveal a tight relation between aCL and hypertension or diabetes mellitus (28) . Our laboratory also illustrates no association between hypertension and anti-beta2-glycoprotein I antibody, another popular antiphospholipid antibody (29) . Therefore, aCL is not favored simply as an inflammatory marker in response to, but an important risk factor for cerebral ischemia with large-artery atherosclerosis.
Accumulating evidence undoubtedly support aCL in promoting atherogenesis (30) . The aCL independently predicts the intima thickness of the carotid artery in humans (31) . In LDL-receptor-deficient knockout mice, immunization of aCL recovered from patients results in the development and acceleration of atherosclerosis (32) . The β 2 GPI and oxidized low-density lipoprotein cholesterol may serve as autoantigen, initiating subsequent autoimmune reaction. The aCL recognizes and enhances marcophage uptake of cardiolipin-beta 2 -glycoprotein I complex (33) . An elevation of very-low-density lipoprotein cholesterol or triglyceride, or a decrease of total cholesterol, high density lipoprotein-cholesterol, or apoprotein A, as in SLE patients, predisposes to atherosclerosis in association with an increased aCL. It may be that cardiolipin binds with the β 2 GPI within lipoproteins to facilitate an activation of humoral immunity for aCL generation in these patients. In our series, we do not find a parallel change of blood lipids and aCL, suggesting a different pathogenesis of aCL generation between patients with and without SLE.
In addition, a concomitant increase in autoantibodies to oxidized low-density lipoprotein, prothrombin, β 2 GPI, or endothelial cells has occasionally been detected in association with an increase of aCL. These autoantibodies disturb the endothelial cell function, compete for the phospholipid surface, mitogenate vascular smooth muscle cell, or generate thrombin formation. They may ignite or intensify the vasculopathic effect of aCL.
The aCL also increases in our patients with stroke of unknown etiology. In these patients, we do not find an abnormal lipid profile, cardiac disease, or significant cerebral atherosclerosis, suggesting that their cerebral occlusive event may result from rheological change. The aCL may accomplish with protein C resistance, upregulation of tissue factor or plasminogen activator inhibitor type-I, leading to an impairment of coagulation or fibrinolysis. Therefore, we think that an increase of aCL in this subtype of patients may reflect a perturbation of the hemostasis milieu. In fact, a diversity of functional detriments is found by aCL in clinical settings. Such as in our patients the frequency of prolonged clotting time, positivity of Coombs' test and VDRL or leukopenia is much less in SLE patients associated with an increase of antiphospholipid antibodies (34) . Subtype or subspecificity of aCL may be present, with distinct consequences.
In some previous reports, increased aCL in cerebral ischemia is emphasized in young adults (18, 35) . We do not find a similar result in this series, akin to a clinical study in Taiwan (36) in that no relation is seen between age and the frequency of increased aCL in stroke.
The elevation of aCL in cerebral ischemia may reflect an involvement of humoral immunity in atherothrombosis. Currently, the relation between antiphospholipid antibody and vascular disease has been extensively investigated worldwide. This model successfully provides an answer to the puzzling question as to whether a key factor corresponds to multiple events observed in atherothrombosis. Further investigation is, of course, warranted.
In conclusion, an increase of aCL-IgG is found in cases of cerebral ischemia with large-artery atherosclerosis and unknown etiology, reflecting multiplanar activation of aCL generation. The results in this study remind us of the crucial role of antiphospholipid antibody in the pathogenesis and development of cerebral ischemia in Asians.
